Astellas Pharma Inc.
Overview of FY2025 Financial Results
FY2025 revenue reached ¥2,139.2 billion (YoY +11.9%), core operating income was ¥555.7 billion (YoY +41.6%), and net income was ¥291.6 billion (YoY +474.6%), marking record highs.
Key Figures
- Revenue: ¥2,139.2 billion (YoY +11.9%)
- Core Operating Income: ¥555.7 billion (YoY +41.6%)
- Net Income Attributable to Owners of Parent: ¥291.6 billion (YoY +474.6%)
AI要約
Overview of FY2025 Results
The consolidated financial results for FY2025 showed revenue of ¥2,139.2 billion, up 11.9% year-over-year, achieving a record high. Selling, general and administrative expenses remained steady, improving the SG&A ratio to 28.6%. Core operating income rose 41.6% YoY to ¥555.7 billion, with the core operating margin increasing to 26.0%. Operating income reached ¥382.6 billion, and net income attributable to owners of parent rose significantly to ¥291.6 billion. Growth was driven by key strategic products, notably PADCEV, IZERVAY, and VYLOY.
FY2026 Outlook and Pipeline Progress
For FY2026, revenue is projected to exceed ¥2.2 trillion (YoY +4%), and core operating income is expected to surpass ¥600 billion (YoY +12%). While anticipating further improvement of the SG&A ratio and increased R&D expenses, growth will be supported by the expansion of key strategic products and cost optimization. The pipeline includes multiple submission and approval-related events centered on PADCEV, as well as progress in new clinical programs such as the initiation of Phase III bladder preservation therapy trials.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
